Compare MobilEye Global Inc (MBLY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MobilEye Global Inc vs Mesoblast Limited — how do they compare? MobilEye Global Inc trades at $9.04 (market cap $7.54B), while Mesoblast Limited trades at $16.32 (market cap $2.17B). The key difference: MobilEye Global Inc is far larger — about 3.5× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals.
| MBLY | MESO | |
|---|---|---|
Market Cap | $7.54B | $2.17B |
Sector | Technology | Technology |
52-Week High | $16.19 | $20.96 |
52-Week Low | $6.56 | $12.88 |
Enterprise Value | $6.19B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mobileye (MBLY) trades at $8.95, down 2.93% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $392 million in 2025 despite revenue of $1.89 billion, reflecting negative profit margins. Recent news highlights its strategic shift toward launching a vertically integrated U.S. robotaxi service in 2027, generating significant media attention and analyst coverage.
The outlook hinges on execution of its robotaxi initiative, offering growth potential but carrying high execution risk. Analyst consensus is bullish with a $10.71 price target, yet profitability challenges and competitive pressures pose substantial risks. Investors should weigh the long-term transformation against current financial weakness.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
